Parexel Consulting Business Slowed By Fewer FDA GMP Enforcement Actions
Parexel's manufacturing compliance consulting business has slowed because of fewer FDA good manufacturing practice enforcement actions
You may also be interested in...
Industry is ready to "embrace" pharmacogenomic-based drug development as long as commercial and regulatory applications are based on a full understanding of the technology, AstraZeneca VP-Clinical Development Glenn Gormley, MD/PhD, said during FDA's risk management public workshop April 9
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials